Eisai Celebrates Launch of new Belgium Operation

               Eisai Celebrates Launch of new Belgium Operation

  PR Newswire

  HATFIELD, England, September 16, 2013

HATFIELD, England, September 16, 2013 /PRNewswire/ --

First drug reimbursement submission for new office is Halaven ^® (eribulin), a
                 novel treatment for advanced breast cancer 

Eisai EMEA (Europe, Middle East, Africa, Russia and Oceania), a division of
one of the world's leading research and development (R&D) based pharmaceutical
companies, has opened a new business operation in Belgium with an office based
in Brussels.

The Belgium office will be responsible for marketing Eisai's Inovelon ^®
(rufinamide), indicated as an adjunctive therapy in the treatment of epileptic
seizures associated with Lennox-Gastaut syndrome (LGS) in patients 4 years and
older, ^[1] which has been commercially available in Belgium since March 2012.
Rufinamide was granted orphan drug status for adjunctive treatment of patients
with this particularly hard-to-treat syndrome in October 2004.

Eisai has submitted Halaven ^® (eribulin), an innovative metastatic breast
cancer (MBC) treatment, for local reimbursement approval by INAMI/RIZIV in
Belgium. Eribulin received European Commission approval in March 2011 and is
indicated for the treatment of patients with locally advanced or MBC who have
progressed after at least two chemotherapeutic regimens for advanced disease.
Prior therapy should have included an anthracycline and a taxane unless women
were not suitable for these treatments. ^[2] 

Commenting on the submission of eribulin for reimbursement approval in
Belgium, Nicolas Kormoss, M.D., Medical Director for Belgium and Luxemburg,
Eisai EMEA said: "Belgium has one of the highest rates of breast cancer in the
world, with around 2,500 women dying from breast cancer every year. We hope
the local health authorities recognise the clinical value that Halaven could
bring to those in the country with advanced breast cancer." ^[3]

The Belgium office opening comes as part of Eisai's globalisation strategy set
out in its mid-term strategic plan in 2011 "HAYABUSA", in which the company
seeks to expand its global presence by 2015 in an effort to achieve its
objective to make contributions to more than 500 million patients worldwide.

Commenting on the opening of the new Belgium office Gary Hendler, President
and CEO, Eisai EMEA said: "We are delighted to open an Eisai office in such a
key European market, both to support Inovelon and to provide a solid base for
the launch of Halaven in the future."

Eisai is committed to developing and delivering highly beneficial new
treatments to help improve the lives of people with cancer and epilepsy, and
their families. The continued development of its oncology and epilepsy
portfolios underscores Eisai's human health care mission, the company's
commitment to innovative solutions in disease prevention, cure and care for
the health and wellbeing of people worldwide.

Notes to Editors

Eisai in Oncology

Our commitment to meaningful progress in oncology research, built on
scientific expertise, is supported by a global capability to conduct discovery
and preclinical research, and develop small molecules, therapeutic vaccines,
and biologic and supportive care agents for cancer across multiple
indications.

About Eisai Europe in Epilepsy

Eisai is committed to developing and delivering highly beneficial new
treatments to help improve the lives of people with epilepsy. The development
of AEDs is a major strategic area for Eisai in Europe, the Middle East,
Africa, Russia and Oceania (EMEA).

In the EMEA region, Eisai currently has four marketed treatments including:

  *Zonegran ^® (zonisamide) as monotherapy and adjunctive therapy in adult
    patients with partial-onset seizures, with or without secondary
    generalisation. (Zonegran is under license from the originator Dainippon
    Sumitomo Pharma)
  *Zebinix ^® (eslicarbazepine acetate) as adjunctive therapy in adult
    patients with partial-onset seizures, with or without secondary
    generalisation. (Zebinix is under license from BIAL)
  *Inovelon ^® (rufinamide) for the adjunctive treatment of seizures
    associated with Lennox-Gastaut Syndrome in patients >4 years
  *Fycompa ^® (perampanel) for use as an adjunctive treatment for partial
    onset seizures, with or without secondarily generalised seizures, in
    patients with epilepsy aged 12 years and older

About Eisai

Eisai is one of the world's leading research and development (R&D) based
pharmaceutical companies and we define our corporate mission as "giving first
thought to patients and their families and to increasing the benefits health
care provides," which we call human health care ( hhc ).

Eisai concentrates its R&D activities in three key areas:

  *Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight
    loss
  *Oncology including: anticancer therapies; tumour regression, tumour
    suppression, antibodies, etc
  *Vascular/Immunological reaction including: thrombocytopenia, rheumatoid
    arthritis, psoriasis, inflammatory bowel disease

With operations in the U.S., Asia, Europe and its domestic home market of
Japan, Eisai employs more than 10,000 people worldwide. From its EMEA
Knowledge Centre in Hatfield, UK, Eisai has recently expanded its business
operations to include Europe, the Middle East, Africa, Russia and Oceania
(EMEA). Eisai EMEA has sales and marketing operations in over 20 markets,
including the United Kingdom, France, Germany, Italy, Spain, Switzerland,
Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Czech Republic,
Slovakia, the Netherlands, Belgium, and the Middle East.

For further information please visit our web site http://www.eisai.co.uk

References 1. Eisai Ltd 2013. Inovelon Summary of Product Characteristics [
http://www.medicines.org.uk/emc/medicine/20165/SPC/Inovelon+Tablets+and+Oral+Suspension
] (last updated August 2013) 2. Eisai Ltd 2013. Halaven Summary of Product
Characteristics [
http://www.medicines.org.uk/emc/medicine/24382/SPC/Halaven+0.44+mg+ml+solution+for+injection
] (last updated April 2013) 3. Globocan 2008 statistics.
http://globocan.iarc.fr/factsheet.asp#WOMEN [
http://globocan.iarc.fr/factsheet.asp ]. Last accessed July 2013.

Date of preparation: September 2013 Job code: Corporate-UK2016

Contact: Media Enquiries: Eisai Europe Ltd, Cressida Robson / Charlotte
Andrews, +44(0)7908-314-155/+44(0)7947-231-513, Cressida_Robson@eisai.net,
Charlotte_Andrews@eisai.net; Tonic Life Communications: Frances Murphy/Nicola
Lilley, +44(0)207-798-9262 /+44(0)207-798-9905, frances.murphy@toniclc.com,
nicola.lilley@toniclc.com
 
Press spacebar to pause and continue. Press esc to stop.